statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Jasper Therapeutics initiated with bullish view at Evercore ISI, here's why

REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...

Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

RBC starts Jasper Therapeutics at outperform, cites market opportunity...

RBC starts Jasper Therapeutics at outperform, cites market opportunity

REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...

Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

REDWOOD CITY, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria

TD Cowen started coverage on shares of Jasper Therapeutics (NASDAQ:JSPR  Get Free Report) in a report issued on Monday, Briefing.com reports. The firm set an outperform rating on...

Jasper Therapeutics (NASDAQ:JSPR) Earns Outperform Rating from Analysts at TD Cowen

Jasper Therapeutics initiated with bullish view at TD Cowen, here's why

Jasper Therapeutics presents Phase 1b/2a data on briquilimab

Three additional patients with Fanconi Anemia treated with briquilimab prior to stem cell transplantAll six patients with Fanconi Anemia treated with briquilimab achieved full donor engraftment and...

New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia

Jasper Therapeutics, Inc. (NASDAQ:JSPR  Get Free Report) has been given a consensus rating of Buy by the five brokerages that are covering the stock, Marketbeat.com reports. Five...

Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $63.70

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.

Volume	44,701.00
52-Wk High	$31.01
52-Wk Low	$4.00

JSPR Jasper Therapeutics Inc

About

Feed

News

Sentiment

Fundamentals